Medtronic Completes $585M Acquisition of CathWorks to Bolster AI-Driven Cardiovascular Portfolio

Recently, Medtronic, the global leader in medical devices, announced that it has completed the acquisition of CathWorks, significantly investing in the cardiovascular sector.

Image Source: Medtronic Official Website

01

Cardiovascular Track

Continuous Scaling Up

It is reported that CathWorks was founded in 2013 and has been dedicated to the development since its establishment.Cardiovascular Imaging and Treatment Solutions Based on Computer Vision and Artificial Intelligence Technology, committed to providing objective data for percutaneous coronary intervention (PCI) decision-making. Notably, Medtronic's acquisition of CathWorks was not accidental but rather the result of nearly eight years of progressive integration.

As early as 2018, Medtronic had already held a minority stake in CathWorks; in 2022, the relationship between the two parties was further upgraded to a strategic partnership, at which time Medtronic invested approximately $75 million to jointly promote CathWorks' core products in the U.S., European, and Japanese markets.FFRangio System。

On February 3, 2026, Medtronic officially announced the exercise of its option to acquire up to$585 million(Approximately RMB 3.987 billion) to acquire CathWorks; On April 20, Medtronic officially announced the completion of the acquisition of CathWorks.

According to the PharmaSmart medical device data query, currentlyCathWorks has launched 2 products in the United States.The product that has been launched is the core product of CathWorks mentioned above, the FFRangio system. Medtronic's acquisition of CathWorks through this options agreement is also based on the excellent clinical performance and market feedback of FFRangio.

Image Source: PharmaSmart Medical Device Data

It is reported that the FFRangio system combinesAI Technology and Advanced Computing Science, aiming to quickly and reliably obtain fractional flow reserve (FFR, a diagnostic technique for assessing the physiological impact of coronary artery stenosis) values from conventional angiography (X-ray), thereby eliminating the need for drug stimulation and invasive pressure wires, and disrupting the limitations of traditional products.

Moreover, the one-year outcome data from the large randomized controlled trial, ALL-RISE, presented at the 2026 American College of Cardiology Annual Meeting, also showed excellent results for the FFRangio system, which also featuresShorter operation time and higher resource utilizationFeatures such as...

This acquisition of CathWorks will also help Medtronic further enhance its cardiovascular product portfolio, solidify its leading position in the cardiovascular field, and increase its competitiveness in this sector. Moreover, amid the AI wave, Medtronic is expected to leverage AI to achieve intelligent upgrades in diagnostic and treatment processes.

Notably, Medtronic is continuously expanding its presence in the cardiovascular sector. Recently,Medtronic Led Pulnovo Medical’s $100 Million Strategic Financing Round`, and has signed a commercial cooperation agreement with it. With heavy investment, Medtronic's cardiovascular track layout is rapidly expanding through a combination of "in-house R&D + mergers and acquisitions + strategic investments."`

02

Strong Growth

"Reinforcement-type" M&A

In recent years, Medtronic has shown strong overall development momentum, with several potential products being approved successively. According to the query from PharmaDJ Medical Device Data, Medtronic8,003 products have been launched in the U.S., and 382 products have been launched in China., with a rich product pipeline covering multiple fields.

Image Source: Pharmcube Medical Device Data

Based on a rich product portfolio, Medtronic's latest financial report showed outstanding performance. On February 17, 2026, Medtronic announced its financial results for the third quarter of fiscal year 2026 (ended January 23, 2026), with quarterly revenue reaching$90 Billion, an increase of 8.7% year-on-year, andSet the strongest growth record in nearly 10 quarters。

In the structure of each business segment, all four segments of Medtronic experienced growth at varying rates. Among them, the cardiovascular business remains the core growth driver of Medtronic.Achieved revenue of $3.457 billion, a year-on-year increase of 13.8%., making it the fastest-growing segment among the four major sectors. The key driving force behind this growth isCardiac Pulse Field Ablation (PFA) Business, with the business surging 80% in a single quarter., increased by 137% in the United States, showing overall excellent performance. The product series includes Pulseselect, Affera Radiofrequency Ablation System, Sphere-9 Catheter, etc., and is one of the important growth points for Medtronic's current development.

In addition, among the remaining three major business segments:Neuroscience BusinessCombination ($2.558 billion, increased by 4.1%); Medical Surgical Portfolio ($2.173 billion, increased by 4.9%);Diabetes Business($796 million, increased by 14.8%), although the growth of some businesses has slowed down, the overall trend is still upward.

Notably, Medtronic's diabetes business has recently completed its spin-off. On March 6, it was officially listed under the name MiniMed with the stock code "MMED," at an issue price of $20, raising $560 million. This spin-off is also part of Medtronic's strategy in recent years.Implement Business Streamlining StrategyThe continuation.

Since 2023, Medtronic has successively divested its renal care business through the joint venture Mozarc Medical and exited the ventilator business in 2024, continuously focusing its portfolio on high-growth, high-margin areas. The diabetes business, being the smallest revenue segment of Medtronic, is both a strategic necessity for focus and provides this business with more flexible growth opportunities.

While streamlining its operations, Medtronic is also increasing the intensity of its "bolstering" acquisitions, rapidly filling gaps in its product pipeline within strategically focused areas, further strengthening its technology and forming synergies.

03

Conclusion

Overall, Medtronic's current strategic map mainly involves divesting smaller or slower-growing businesses to focus on high-growth sectors, while strengthening its technological moat through mergers and acquisitions, investments, and more. With the completion of another promising deal, Medtronic is entering a new development cycle with a sharper edge.

References: Medtronic official website, financial reports